Option chain shows key data for Ambev's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ambev.

Ambev (NYSE:ABEV) Stock, Option Chain

Ambev

Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving Interbrew (now AB InBev) a controlling interest of 61.8% as at the end of 2023.

beer-2425247_1920

Earnings

Equities

News

Markets

Movers

General

ABEV

Ambev&#39;s Q3 earnings matched estimates but missed sales expectations, leading to a drop in shares amid stalled volume growth.

Ambev Q3 Sales Miss Expectations As Volume Growth Stalls; Shares Dip

xr:d:DAE9HpS4rJc:11614,j:6090407153246692692,t:24010517

Latin America

Technicals

Signals

Trading Ideas

Ambev (NYSE:ABEV) is showing potential for a Golden Cross, indicating a positive trend. With strong market dominance and growth potential, ABEV&#39;s stock is poised for a rebound. Its fundamentals and attractive valuation make it a solid long-term investment.

Is A Golden Cross Brewing For Ambev? Technical Charts Show Bullish Potential

man-2425121

Ambev shares are trading higher by 2.4% Thursday morning. The company reported better-than-expected second-quarter sales results.

Why Ambev (ABEV) Stock Is Rising Following Q2 Earnings

Ambev S.A. American Depositary Shares (Each representing 1 Common Share)

Ambev SA

Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) shares<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> are trading lower on Thursday.</a>
The company <a target="_blank" href="https://api.mziq.com/mzfilemanager/v2/d/c8182463-4b7e-408c-9d0f-42797662435e/9d220ab4-acad-1bc2-6ca3-30487b33d05a?origin=1" rel="noreferrer noopener">reported </a>third quarter earnings per share of 4 cents, in line with the street view. Quarterly sales of $3.983 billion missed the analyst consensus estimate of $4.082 billion.
Consolidated volumes declined by 0.6%, but when excluding Argentina, there was a growth of 1.3%.
In Brazil, volumes increased by 1.3%, with beer sales growing by 0.6% and non-alcoholic beverages (NAB) rising by 3.4%. In Brazil&#8217;s beer segment, premium and super premium brands saw volume growth in the low twenties, driven by Corona, Spaten, and Original. Core plus brands grew by low teens, with the Budweiser family leading the way, while core brands Brahma and Antarctica each recorded high single-digit increases in volume.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41658099/cheez-it-parent-kellanovas-q3-earnings-organic-sales-climb-mars-buyout-vote-nears-more" rel="noreferrer noopener">Cheez It Parent Kellanova&#8217;s Q3 Earnings: Organic Sales Climb, Mars Buyout Vote Nears &amp; More</a>
In Central America and the Caribbean (CAC), volumes decreased by 0.5%, although the Dominican Republic saw a midsingle-digit increase. Additionally, soft industry conditions in Argentina and Canada contributed to volume declines of 7.7% in Latin America South (LAS) and 1.4% in Canada.
In the quarter under review, the company&#8217;s cash cost of goods sold (COGS) increased in low-single digits, primarily due to inflation and diminished benefits from commodity price hedges, while cash selling, general, and administrative expenses (SG&amp;A) rose in mid-single digits because of increased investments in brand support and higher administrative costs linked to elevated variable compensation accruals.
&#8220;Looking ahead, we remain focused on executing our commercial strategy and are confident in our preparedness for the Summer season in South America, with healthier brands and sustained all-time-high NPS levels,&#8221; Ambev said.
Price Action: ABEV shares are trading lower by 3.08% to $2.20 at last check Thursday.
Photo: Engin Akyurt from Pixabay
Also Read:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41653721/est-e-lauder-q1-earnings-china-uncertainty-hits-beauty-giant-withdraws-fy25-outlook-stock-tanks" target="_blank" rel="noreferrer noopener">Estée Lauder Q1 Earnings: China Uncertainty Hits Beauty Giant, Withdraws FY25 Outlook, Stock Tanks</a></li>
</ul>

Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. The company reported quarterly sales of $3.983 billion which missed the analyst consensus estimate of $4.082 billion by 2.43 percent. This is a 4.30 percent decrease over sales of $4.162 billion the same period last year.

Earnings Misses

Ambev Q3 2024 GAAP EPS $0.04, Inline, Sales $3.983B Miss $4.082B Estimate

Ambev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) is inching <a href="https://www.benzinga.com/topic/golden-cross">towards a golden cross</a>—a technical signal that could suggest brighter days ahead for the stock.
As one of the largest beverage giants, Ambev has been a key player in Latin America&#8217;s beer market, dominating countries like Brazil, Argentina, and the Dominican Republic. 
But, after a challenging year with stock price declines and currency woes, could this golden cross be the turning point?
<h2 class="wp-block-heading">Ambev's Brewing Success In Latin America</h2>
Ambev isn't just any beer company. With control over <a href="https://www.moneymag.com.au/why-you-should-buy-ambev-shares-october-2024">66%</a> of Brazil&#8217;s beer market, a near-monopoly in the Dominican Republic, and substantial stakes in Argentina and Canada, this giant knows how to dominate. The company, a key part of AB InBev, has a knack for using its scale to drive profits, with a strategic focus on premium brands. 
This shift towards premium beers, coupled with steady price increases, helped Ambev weather market turbulence.
After a slowdown in 2023, Ambev is rebounding in 2024. Growth picked up in the second quarter, and with stabilizing commodity prices, the company is poised to improve margins by 2027. With an expected expansion of operating margins and continued pricing power, Ambev is looking to shake off the recent slump.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
<h2 class="wp-block-heading">Golden Cross On Tap: Is ABEV Ready To Shine?</h2>
For technical traders, a golden cross is a big deal—it happens when the 50-day moving average crosses above the 200-day moving average, signaling potential bullish momentum. Ambev's stock is close to making this move, and while its recent price action has been bearish, this could shift the tide.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24072132/Screenshot-2024-10-24-at-4.01.59-PM.png" alt="" class="wp-image-611723" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24072132/Screenshot-2024-10-24-at-4.01.59-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24072132/Screenshot-2024-10-24-at-4.01.59-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102424&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Currently trading at $2.25, ABEV stock is still below key moving averages, signaling a bearish signal for cautious traders. ABEV stock's eight-day simple moving average stands at $2.29, while the 50-day SMA is $2.35. 
However, with a Relative Strength Index (RSI) of 38.41 and declining, Ambev stock could soon be oversold. This is when we could see some buying pressure starting to emerge. The negative 0.02 of the Moving Average Convergence/Divergence (MACD) indicator also suggests it's time to take a closer look.
<h2 class="wp-block-heading">Why Ambev&#8217;s Valuation Matters Now</h2>
Despite the technical picture, Ambev's fundamentals remain strong. Trading at a discount to historical averages, the stock offers upside potential for both price appreciation and income, with a <a href="https://www.benzinga.com/quote/ABEV/dividends">dividend yield of 6.71%</a>. The company's ability to generate strong cash flows and impressive balance sheet, including a net cash position of 10.7 billion reals (approx. $1.88 billion), make it an attractive option for long-term investors.
With third-quarter earnings approaching, now could be the time to watch Ambev stock closely. A positive earnings surprise might be the catalyst to push the stock through the golden cross threshold and into bullish territory.
Ambev's golden cross is almost here, and for savvy traders, this could mark a buying opportunity. 
While the stock has been down in 2024, its dominance in Latin America, coupled with a strong balance sheet and recovering margins, positions it well for a turnaround.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41513495/brics-summit-2024-russian-president-calls-for-de-dollarization-heres-how-it-could-impact-us-investor">BRICS Summit 2024: Russian President Calls For De-Dollarization, Here&#8217;s How It Could Impact US Investors</a></li>
</ul>
Photo: Shutterstock

Ambev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) shares are trading higher by 0.97% to $2.08 Thursday morning after the company reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/ABEV/earnings">sales results</a>.
<h2 class="wp-block-heading">What Happened?</h2>
Ambev reported quarterly earnings of&nbsp;3 cents&nbsp;per share which met the analyst consensus estimate. The company reported quarterly sales of&nbsp;$3.847 billion&nbsp;which beat the analyst consensus estimate of&nbsp;$3.609 billion&nbsp;by&nbsp;6.6%. This figure represents a&nbsp;0.76%&nbsp;increase over sales of&nbsp;$3.818 billion&nbsp;in the same period last year.
Ambev&#8217;s CEO, Jean Jereissati, highlighted double-digit growth in Normalized EBITDA and margin expansion driven by commercial momentum and operational leverage. Total volumes showed a slight increase of 0.4% year-over-year (YoY), with net revenue rising by 4.8% YoY.
Read Also: <a href="https://www.benzinga.com/news/24/08/40101256/why-ocugen-ocgn-stock-is-falling">Why Ocugen (OCGN) Stock Is Falling</a>
The growth was primarily led by Brazil, which saw a 4.1% increase in volumes, including a 7.7% rise in non-alcoholic beverages (NAB) and a 2.9% increase in beer. Central America and the Caribbean (CAC) also experienced a 3.4% volume increase. However, volumes declined in Latin America South (LAS) by 13.7% and in Canada by 6.9%.
Net revenue per hectoliter (NR/hl) grew by 4.5%, contributing to overall net revenue increases in most business units: Brazil NAB rose by 15.0%, CAC by 8.4%, Brazil Beer by 6.9% and LAS by 0.5%, while Canada saw a 5.7% decline due to volume decreases. 
Normalized EBITDA meanwhile increased by 15.9% YoY, driven by strong performance in Brazil (23.5% growth), CAC (17.9%), and LAS (7.6%), despite a 2.2% decline in Canada. Gross margin expanded by 200 basis points (bps), and Normalized EBITDA margin grew by 300 bps.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/08/40101240/meta-platforms-stock-is-rallying-thursday-whats-going-on">Meta Platforms Stock Is Rallying Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy ABEV Stock</h2>
By now you're likely curious about how to participate in the market for Ambev &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stocks, like Berkshire Hathaway can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Ambev, which is trading at $2.06 as of publishing time, $100 would buy you 48.54 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ABEV has a 52-week high of $3.13 and a 52-week low of $2.01.

Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. The company reported quarterly sales of $3.847 billion which beat the analyst consensus estimate of $3.609 billion by 6.59 percent. This is a 0.76 percent increase over sales of $3.818 billion the same period last year.

Earnings Beats

Ambev Q2 2024 Adj. EPS $0.03, Inline, Sales $3.847B Beat $3.609B Estimate

UBS maintains Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) with a Buy and lowers the price target from $3.2 to $2.9.

Price Target

Analyst Ratings

UBS Maintains Buy on Ambev, Lowers Price Target to $2.9

Beer shares, including Anheuser-Busch Inbev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>), Ambev S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) and Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), are trading lower Monday following a weak earnings report from Heineken Holding N.V. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HKHHF#OTC">HKHHF</a>)
What Happened: Heineken its half-year results, showing revenue of €17.82 billion ($19.29 billion) and operating profit of €1.54 billion. Despite achieving organic growth in beer volume and Heineken volume, Heineken&#8217;s net profit was impacted by non-cash impairments, leading to a net loss of €48 million. The outlook for the full year has been updated, with operating profit expected to grow organically by 4% to 8%.
Upcoming Earnings:
<ul>
<li>Anheuser-Busch Inbev is set to report second-quarter earnings on August 1st before market open, with an estimated EPS of 87 cents and estimated revenue of $15.56 billion.</li>
<li>Ambev S.A. will also report second-quarter earnings on August 1st before market open, with an estimated EPS of 3 cents and estimated revenue of $3.71 billion.</li>
<li>Molson Coors Beverage Company is scheduled to report second-quarter earnings on August 6th before market open, with an estimated EPS of $1.68 and estimated revenue of $3.18 billion.</li>
</ul>
Why It Matters: The weak performance of Heineken has had a ripple effect across the beer industry. With upcoming earnings reports from other major beer companies, the market is cautious about the potential for similar disappointing results. 
Price Action:
<ul>
<li>Anheuser-Busch Inbev shares are down 2.31% at $59.96.</li>
<li>Ambev S.A. shares are flat at $2.11.</li>
<li>Molson Coors Beverage Company shares are down 2.10% at $53.19.</li>
</ul>
Photo: Engin Akyurt from Pixabay.

HKHHF

Beer Companies Shares Are trading Lower Today: What You Need To Know

WIIM

Shares of beer companies are trading lower following weak earnings from Heineken.

AZUL

ITUB

Shares of US-listed Brazilian stocks are trading lower following Brazil's Central Bank decision.

Barclays analyst Benjamin Theurer maintains Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) with a Equal-Weight and lowers the price target from $3 to $2.5.

Barclays Maintains Equal-Weight on Ambev, Lowers Price Target to $2.5

Brazilian brewing company&nbsp;Ambev SA&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>)&nbsp;<a target="_blank" href="https://api.mziq.com/mzfilemanager/v2/d/c8182463-4b7e-408c-9d0f-42797662435e/0bdf4318-e6ab-cb8e-c44e-3aee4060421a?origin=1" rel="noreferrer noopener">reported&nbsp;</a>first-quarter&nbsp;FY24 net revenue decline of 1.2% to R$20.3 billion. On an organic basis, net revenue gained 4.5%.&nbsp;Net&nbsp;revenue&nbsp;per&nbsp;hl&nbsp;slipped&nbsp;1.4%.
Consolidated volume was virtually flat (+0.1%), as positive performances in Brazil (+6.5% in NAB and +3.6% in Beer) and Central America and the Caribbean (CAC) (+5.6%)&nbsp;were offset&nbsp;by Latin America South (-12.7%) and Canada (-7.7%).
Gross profit for the quarter dropped 1.8% to R$10.2 billion, and the margin contracted 30 basis points to 50.4%.
Normalized profit dropped 0.6% to R$3.8 billion. Normalized EBITDA climbed 1.4% to R$6.5 billion, and the normalized EBITDA margin expanded by 80 basis points to 32.2%.
Ambev held R$12.8 billion in cash and equivalents as of March-end.
&#8220;Our continued commercial momentum delivered a&nbsp;strong start to&nbsp;the year with double-digit&nbsp;Normalized
EBITDA growth (with margin expansion),&#8221; said CEO Jean Jereissati.
Price Action: ABEV shares are trading lower by 3.66% at $2.37 at&nbsp;the last check Wednesday.

Brewing Company Ambev Posts 4.5% Organic Revenue Growth In Q1

Ambev shares are trading lower after the company reported Q1 financial results.

Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $4.10 billion which beat the analyst consensus estimate of $3.85 billion by 6.39 percent. This is a 3.64 percent increase over sales of $3.95 billion the same period last year.

Ambev Q1 Adj $0.05 Beats $0.04 Estimate, Sales $4.10B Beat $3.85B Estimate

Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one <a href="https://www.benzinga.com/quote/SBUX/news">such opportunity window.</a>
We looked at established companies that, recently, made new 52-week lows. We point readers&#8217; attention to three such stocks, with $35 billion market capitalizations. These are: Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Ambev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>).
<h2 class="wp-block-heading">Starbucks</h2>
Trading at around $86.83, the coffee franchise&#8217;s stock could potentially offer a buy-the-dip opportunity. The Seattle-based company&#8217;s shares command a market cap of over $98 billion on the stock market and sport an average three-month trading volume of 8.49 million.
The stock also offers, to its investors, a dividend yield of 2.63%.
Wells Fargo, TD Cowen, and TD Cowen released the last three analyst ratings on April 1, April 1, and March 19, 2024, respectively. These ratings suggest an average price target of $102.33 for Starbucks Corp, implying a potential upside of 17.23% based on the assessments of these three analysts.
Also Read: <a href="https://www.benzinga.com/insights/news/24/03/37971829/100-invested-in-this-stock-15-years-ago-would-be-worth-1-600-today">$100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today</a>
<h2 class="wp-block-heading">Gilead Sciences</h2>
Trading at around $69.32, this biopharma stock is currently trading about its 52-week lows. The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, including medications such as Truvada, Atripla, and Descovy.
Gilead stock offers a robust dividend yield of 4.43%.
Wells Fargo, Mizuho, and Truist Securities recently released the last three analyst ratings. These assessments collectively suggest an average price target of $83.33 for Gilead stock.
Based on these ratings, there is an implied 20.16% upside potential for the company.
<h2 class="wp-block-heading">Ambev</h2>
Ambev SA is widely renowned for its portfolio of beer brands, including popular labels such as Skol, Brahma, Antarctica, and Budweiser. Trading at $2.40, Ambev stock is near-about its 52-week low level of $2.36. The stock also offers a juicy dividend yield of 6.26%.
Based on the analysis of the 8 latest analyst ratings, Ambev SA has a consensus price target of $2.2. The most recent ratings were issued by Barclays, Jefferies, and Bernstein on March 4, 2024, Nov. 22, 2023, and May 24, 2023, respectively. 
These assessments collectively indicate an average price target of $3.2 for Ambev stock. Consequently, there&#8217;s an implied 32.51% upside potential for the company based on these three analyst ratings.
These findings suggest that these quality stocks may present lucrative investment opportunities, offering potential upside for investors in the coming months.
Read Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38032100/redditors-identify-best-undervalued-stocks-for-2024">Redditors Identify &#8216;Best Undervalued Stocks&#8217; For 2024</a>

Long Ideas

GILD

SBUX

Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) alongside its primary competitors in the Beverages industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
<h3>Ambev Background</h3>
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving Interbrew (now AB InBev) a controlling interest of 61.8% as at the end of 2023.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambev SA</td>
<td>13.48</td>
<td>2.46</td>
<td>2.45</td>
<td>5.19%</td>
<td>$6.95</td>
<td>$10.69</td>
<td>-11.91%</td>
</tr>
<tr>
<td>Anheuser-Busch InBev SA/NV</td>
<td>23.40</td>
<td>1.47</td>
<td>2.10</td>
<td>2.31%</td>
<td>$3.61</td>
<td>$7.79</td>
<td>-1.33%</td>
</tr>
<tr>
<td>Molson Coors Beverage Co</td>
<td>15.41</td>
<td>1.08</td>
<td>1.25</td>
<td>0.78%</td>
<td>$0.42</td>
<td>$1.03</td>
<td>6.13%</td>
</tr>
<tr>
<td>Boston Beer Co Inc</td>
<td>49.59</td>
<td>3.44</td>
<td>1.88</td>
<td>-1.65%</td>
<td>$-0.0</td>
<td>$0.15</td>
<td>-12.02%</td>
</tr>
<tr>
<td>United Breweries Co Inc</td>
<td>20.30</td>
<td>1.76</td>
<td>0.84</td>
<td>3.25%</td>
<td>$41.32</td>
<td>$264.27</td>
<td>-16.61%</td>
</tr>
<tr>
<td>Average</td>
<td>27.18</td>
<td>1.94</td>
<td>1.52</td>
<td>1.17%</td>
<td>$11.34</td>
<td>$68.31</td>
<td>-5.96%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After a detailed analysis of Ambev, the following trends become apparent: 
<ul>
<li>
The Price to Earnings ratio of 13.48 is 0.5x lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 2.46 which exceeds the industry average by 1.27x.
</li>
<li>
The Price to Sales ratio of 2.45, which is 1.61x the industry average, suggests the stock could potentially be overvalued in relation to its sales performance compared to its peers.
</li>
<li>
The Return on Equity (ROE) of 5.19% is 4.02% above the industry average, highlighting efficient use of equity to generate profits.
</li>
<li>
With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $6.95 Billion, which is 0.61x below the industry average, the company may face lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $10.69 Billion, which indicates 0.16x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of -11.91% is significantly lower compared to the industry average of -5.96%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711638007_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio assesses the extent to which a company relies on borrowed funds compared to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Ambev stands in comparison with its top 4 peers, leading to the following comparisons:
<ul>
<li>
Compared to its top 4 peers, Ambev has a moderate debt-to-equity ratio of 0.04, indicating a balanced financial structure.
</li>
<li>
This suggests that the company maintains a reasonable level of debt while also leveraging equity financing.
</li>
</ul>
<h3>Key Takeaways</h3>
For PE, PB, and PS ratios, Ambev shows a low PE ratio, indicating potential undervaluation compared to peers. However, its high PB and PS ratios suggest overvaluation relative to industry standards. In terms of ROE, EBITDA, gross profit, and revenue growth, Ambev demonstrates high ROE but low EBITDA, gross profit, and revenue growth compared to industry peers, indicating mixed performance in operational efficiency and growth potential within the Beverages industry.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Performance Comparison: Ambev And Competitors In Beverages Industry

The February labor market report presented mixed signals on the employment front, with a notable and larger-than-expected increase of 270,000 in nonfarm payrolls over the month, yet a higher-than-expected rise in the unemployment rate, moving <a href="https://www.benzinga.com/news/econ-s/24/03/37558250/february-jobs-growth-beats-estimates-but-unemployment-rate-rises-to-3-9-wage-growth-eases">from 3.7% to 3.9%.</a>
Additionally, the employment changes for December and January were revised downwards, subtracting a total of 167,000 nonfarm payrolls previously calculated for those two months.
Perhaps the clearest data came from the trend in wages, which grew less than expected, thereby alleviating fears about their potential impact on inflation.
In February, the pace of increase in average hourly earnings was 0.1%, a decrease from the 0.4% in January and lower than the expected 0.3%. On an annual basis, wage growth is 4.3%, down from the 4.4% expected and from January&#8217;s figure.
Overall, the data from the February labor market report has further fueled market bets on Federal Reserve rate cuts.
Traders assign an 83% probability on a rate cut occurring by June, as per CME Group&#8217;s FedWatch Tool. Additionally, they estimate a total of 105 basis points of cuts by the end of the year, implying a scenario where four cuts are fully priced in.
Stocks slightly increased after the release, with futures on the S&amp;P 500 index up by 0.3%, and those on the tech-heavy Nasdaq 100 inching 0.2% higher. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed at an all-time high on Thursday. 
<h2 class="wp-block-heading">Stock Movers On Friday&#8217;s Morning Trading</h2>
Below is a list of stocks (with at least $10 billion of market capitalization) reacting to the job report release, as indicated by data from the <a href="https://pro.benzinga.com/dashboard">Benzinga Pro platform.</a>
Top Gainers After Jobs Report
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>%Change between 08:30-09:20 ET</td>
</tr>
<tr>
<td>Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)</td>
<td>2.0%</td>
</tr>
<tr>
<td>JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>)</td>
<td>1.87%</td>
</tr>
<tr>
<td>GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)</td>
<td>1.84%</td>
</tr>
<tr>
<td>Petrobras Brasileiro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>)</td>
<td>1.65%</td>
</tr>
<tr>
<td>Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>)</td>
<td>1.58%</td>
</tr>
<tr>
<td>A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>)</td>
<td>1.53%</td>
</tr>
<tr>
<td>Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)</td>
<td>1.52%</td>
</tr>
</tbody>
</table>
</figure>
Worst Losers After Jobs Report
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>%Change between 08:30-09:20 ET</td>
</tr>
<tr>
<td>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)​</td>
<td>-2.59%</td>
</tr>
<tr>
<td>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>)</td>
<td>-1.79%</td>
</tr>
<tr>
<td>Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)</td>
<td>-1.67%</td>
</tr>
<tr>
<td>Suzano S.A.</td>
<td>-1.35%</td>
</tr>
<tr>
<td>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>-1.29%</td>
</tr>
<tr>
<td>Barrick Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>)​</td>
<td>-1.24%</td>
</tr>
<tr>
<td>Ambev S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>)</td>
<td>-1.19%</td>
</tr>
<tr>
<td>Skyworks Solutions</td>
<td>-1.18%</td>
</tr>
</tbody>
</table>
</figure>
Read now: <a href="https://www.benzinga.com/markets/equities/24/03/37554807/happy-womens-day-if-you-had-invested-1000-in-these-female-led-s-p-500-companies-a-year-ago-which">Happy Women&#8217;s Day! If You Had Invested $1,000 In These Female-Led S&amp;P 500 Companies A Year Ago, Which Would&#8217;ve Fetched The Best Returns?</a>
Photo: Shutterstock

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

ETFs

BIIB

GOLD

NICE

PARA

RIVN

SCCO

TEAM

Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers

Barclays analyst Benjamin Theurer downgrades Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) from Overweight to Equal-Weight and lowers the price target from $3.5 to $3.

Downgrades

Barclays Downgrades Ambev to Equal-Weight, Lowers Price Target to $3

The understudied threat of microplastics has become a major source of concern for large <a href="https://www.benzinga.com/topic/population">sectors of the population.</a>
While scientists have not yet identified the exact consequences of living around microscopic pieces of plastic, their presence <a href="https://www.benzinga.com/news/24/01/36575819/bottled-water-contains-far-more-plastic-particles-but-it-is-not-totally-unexpected-study-reveals">has been found in everything from drinking water</a> to human tissue to the air we breathe.
According to a new study, an everyday solution could help get rid of as much as 90% of microplastics in tap water by simply boiling and filtering it.
<h3 class="wp-block-heading">Microplastics: An Invisible Threat</h3>
The term &#8220;microplastics&#8221; refers to small plastic fragments smaller than 5mm, found as contaminants in urban and natural environments. 
They come from multiple sources including plastics already produced in those sizes, like synthetic fibers of clothing or microbeads included in cosmetic products, or they can appear as a result of the degradation of larger plastic products, such as single-use plastic containers like soda bottles and plastic bags.
Nanoplastics, the tiniest fragments, measure as small as one millionth of a meter.
Public concern about microplastics has grown in recent years after several studies have found them in almost every inch of the world around us.
In 2022, a study from the Netherlands detected microplastics in the blood of 80% of sampled individuals from the general population, and another study from the same year discovered microplastics in living heart tissue.
A few months ago, a study from Shandong University in China found them in the clouds above East China.
Microplastics are especially present in drinking water. A 2018 study found them in 93% of bottled water from nine different countries, and a recent review highlighted their detection in tap water from a wide range of countries, including the U.S., Germany, Mexico, France, China, Japan, Saudi Arabia, and Norway.
Also read: <a href="https://www.benzinga.com/news/23/06/32863902/the-end-of-the-plastic-era-world-delegates-forge-ahead-with-draft-plastics-treaty-to-shape-a-greener">The End Of The Plastic Era? World Delegates Forge Ahead With Draft Plastics Treaty To Shape A Greener World</a>
<h3 class="wp-block-heading">Are Microplastics Harmful?</h3>
While the health effects of microplastics exposure are still being researched, several studies have raised red flags about the ubiquitous presence of these particles in daily life. Their health consequences can vary along different variables, which include the type of plastic, the size of the particles, whether they were inhaled, ingested or touched and the length of exposure.
Microplastics have been linked to negative health impacts, including cellular damage and problems within the gastrointestinal and respiratory systems.
According to a WHO report, microplastics can be harmful to the body not only by themselves, but they can also serve as "vectors of pathogens," providing ways for microbes to enter the organism. They can also worsen symptoms of pre-existing conditions like asthma and chronic obstructive pulmonary disease.
While the overall consensus among scientists is that more research is needed to better understand the health impact of microplastics, it's advised to avoid prolonged exposure to foreign particles as there is no precedent in history to understand what happens to a human body that undergoes daily exposure to small plastic particles from the time of birth.
<h3 class="wp-block-heading">Is Boiling Drinking Water The Solution?</h3>
A study published this week in the Environmental Science &amp; Technology journal found that boiling drinking water can reduce at least 80% of polystyrene, polyethylene, and polypropylene, the most commonly-found types of nano/microplastics.
The team of researchers, from Guangzhou Medical University and Jinan University in China, set out to find ways in which regular people could reduce their daily exposure to microplastics using household methods.
The method was more effective for certain types of tap water. Water supplies from around the globe vary in their chemical composition. In waters that are rich in minerals like calcium or magnesium, the boiling process causes these minerals to trap the plastics into a solid, chalky residue that can be removed by filtering the water.
In waters that were rich in these minerals, the process helped capture up to 90% of the microplastic particles. Yet in those samples that carried fewer amounts of the minerals, only about 25% was removed.
For those wanting to try the method at home, the water should be left to cool and settle after boiling without stirring for about 10 minutes and then filtered with a regular coffee filter.
The researchers wrote in the study that boiling drinking water is a tradition in East Asian countries as it helps get rid of some chemicals and most microbes living in the water.
<h3 class="wp-block-heading">Stocks To Watch</h3>
<ul>
<li>Public companies involved in the sale of bottled water include Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), PepsiCo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), Primo Water Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NYSE">PRMW</a>) and Ambev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) and Primo Water Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NASDAQ">PRMW</a>).</li>
<li>Coca-Cola, PepsiCo, Nestle SA &#8211; ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>), MONDELEZ INTERNATIONAL INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Unilever plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>), Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) were ranked among the top plastic polluters of 2022 by the Break Free From Plastic Global Brand Audit.</li>
<li>Some of the largest running water providers include American Water Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) and Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>).</li>
<li>Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) and China Petroleum and Chemical Ord Shs H (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNPMF#OTC">SNPMF</a>) were the top three producers of single-use plastic items in 2021 as per 2023 Plastic Waste Makers Index report. </li>
</ul>
Now read: <a href="https://www.benzinga.com/news/23/06/32842246/with-363-8-billion-pounds-of-plastic-in-the-ocean-plastic-pollution-will-soon-outweigh-fish">With 363.8 Billion Pounds Of Plastic In The Ocean, Plastic Pollution Will Soon Outweigh Fish</a>
Photo: Shutterstock

Education

MDLZ

Nestle Sponsored representing Registered Shares Series B

NSRGY

PRMW

SNPMF

WTRG

Boiling Water Reduces Microplastics: What Does It Mean For Coca-Cola, PepsiCo's Bottled Water Brands?

Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) reported its Q4 earnings results on Thursday, February 29, 2024 at 08:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Ambev beat estimated earnings by 40.0%, reporting an EPS of $0.07 versus an estimate of $0.05.
Revenue was up $268.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 2.0% increase in the share price the next day.
Here's a look at Ambev's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.05</td>
<td>0.03</td>
<td>0.05</td>
<td>0.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>4.24B</td>
<td>3.89B</td>
<td>3.85B</td>
<td>4.60B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.16B</td>
<td>3.82B</td>
<td>3.95B</td>
<td>4.31B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Ambev <a href="https://www.benzinga.com/quote/ABEV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Ambev: Q4 Earnings Insights

Jefferies analyst Alex Wright initiates coverage on Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) with a Hold rating and announces Price Target of $2.86.

Initiation

Jefferies Initiates Coverage On Ambev with Hold Rating, Announces Price Target of $2.86

Ambev S.A. (ABEV) Q3 2024 Earnings Call Transcript

Ambev SA ( ($ABEV) ) has released its Q3 earnings. Here is a breakdown of the information Ambev SA presented to its investors. Ambev SA, a leading ...

Ambev Reports Steady Growth Amid Economic Challenges

In a report released today, Benjamin Theurer from Barclays maintained a Hold rating on Ambev SA (ABEV – Research Report), with a price target of $2...

Barclays Keeps Their Hold Rating on Ambev SA (ABEV)

In a report released today, Robert Ottenstein from Evercore ISI maintained a Buy rating on Ambev SA (ABEV – Research Report), with a price target o...

Evercore ISI Remains a Buy on Ambev SA (ABEV)

4-Factor Dividend Growth Portfolio: FY3 Rebalance And 21.57% Long-Term CAGR

Evercore ISI Keeps Their Buy Rating on Ambev SA (ABEV)

Ambev SA (ABEV) Gets a Hold from Barclays

Ambev SA (ABEV) has released an update. Ambev S.A., a major player in the beverage industry, reported its interim consolidated financial statements...

Ambev S.A. Reports Strong Financial Growth for 2024

Ambev SA (ABEV) has released an update. Ambev SA reported securities transactions for October 2024, revealing a decrease in their common shares bal...

Ambev SA Reports Strategic Securities Transactions for October

Ambev SA (ABEV) has released an update. Ambev S.A., a major player in the beverage sector, reported transactions in its securities for October 2024...

Comments

Ambev

Ambev (ABEV) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga